{"id":"interferon-beta-1","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"40-50","effect":"Injection site reactions"},{"rate":"30-40","effect":"Headache"},{"rate":"30-40","effect":"Fatigue"},{"rate":"10-20","effect":"Elevated liver enzymes"},{"rate":"5-15","effect":"Leukopenia"},{"rate":"5-10","effect":"Depression"}]},"_chembl":null,"_dailymed":{"setId":"66311f74-0472-4fa3-848a-06002ca0def5","title":"BETASERON (INTERFERON BETA-1B) KIT [BAYER HEALTHCARE PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon Beta-1 is a type I interferon that binds to interferon-alpha/beta receptors on cell surfaces, triggering JAK-STAT signaling and upregulating antiviral and immunomodulatory genes. It enhances natural killer cell activity, increases expression of MHC molecules, and reduces pro-inflammatory cytokine production. In multiple sclerosis, it reduces the frequency and severity of relapses by modulating immune cell trafficking and reducing CNS inflammation.","oneSentence":"Interferon Beta-1 activates interferon signaling pathways to enhance immune responses and reduce inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:28.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Secondary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT06698796","phase":"PHASE3","title":"A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-22","conditions":"Dermatomyositis, Polymyositis","enrollment":211},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT06053749","phase":"","title":"An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-03-20","conditions":"Multiple Sclerosis (MS)","enrollment":4},{"nctId":"NCT06508463","phase":"PHASE1","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":"Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified","enrollment":21},{"nctId":"NCT06551519","phase":"","title":"A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-28","conditions":"Multiple Sclerosis","enrollment":700},{"nctId":"NCT03120624","phase":"PHASE1","title":"VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-09-15","conditions":"Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma","enrollment":34},{"nctId":"NCT03865212","phase":"PHASE1","title":"Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2019-06-12","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Choroid Melanoma","enrollment":12},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT01753570","phase":"PHASE3","title":"Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-12","conditions":"Chronic Hepatitis C(CHC)","enrollment":74},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT01892722","phase":"PHASE3","title":"Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07-26","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT05688436","phase":"","title":"A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies","status":"RECRUITING","sponsor":"Biogen","startDate":"2021-09-24","conditions":"Multiple Sclerosis","enrollment":1178},{"nctId":"NCT05895786","phase":"PHASE3","title":"A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-20","conditions":"Myositis","enrollment":318},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT07189325","phase":"PHASE3","title":"A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09","conditions":"Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy","enrollment":250},{"nctId":"NCT05962177","phase":"NA","title":"Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2023-09-11","conditions":"Multiple Sclerosis","enrollment":400},{"nctId":"NCT03647163","phase":"PHASE1, PHASE2","title":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vyriad, Inc.","startDate":"2019-04-09","conditions":"Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma","enrollment":33},{"nctId":"NCT03958877","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biogen","startDate":"2019-10-18","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":152},{"nctId":"NCT05076760","phase":"PHASE1","title":"MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Memgen, Inc.","startDate":"2022-04-21","conditions":"Solid Tumor, Advanced Cancer, Metastatic Cancer","enrollment":40},{"nctId":"NCT03535298","phase":"PHASE4","title":"Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-01-03","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":800},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT05658497","phase":"","title":"Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)","status":"RECRUITING","sponsor":"Biogen","startDate":"2023-10-27","conditions":"Multiple Sclerosis","enrollment":908},{"nctId":"NCT02283853","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-08-28","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":156},{"nctId":"NCT01628640","phase":"PHASE1","title":"Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-08-03","conditions":"Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma","enrollment":17},{"nctId":"NCT03193866","phase":"","title":"COMparison Between All immunoTherapies for Multiple Sclerosis.","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2017-06-02","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":3526},{"nctId":"NCT04278404","phase":"","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-03-05","conditions":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children","enrollment":5000},{"nctId":"NCT03344094","phase":"","title":"Mechanism of Action of Ocrelizumab in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2018-02-23","conditions":"Multiple Sclerosis, Immune System Diseases","enrollment":30},{"nctId":"NCT06812585","phase":"PHASE2","title":"The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study","status":"COMPLETED","sponsor":"German University in Cairo","startDate":"2022-04-01","conditions":"Multiple Sclerosis (MS) - Relapsing-remitting","enrollment":30},{"nctId":"NCT00676715","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-07-17","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":220},{"nctId":"NCT06734663","phase":"NA","title":"Clinical Outcomes of Sutured Versus Sutureless Conjunctival Autograft in Primary Pterygium Excision","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-12-15","conditions":"Pterygium of Conjunctiva and Cornea, Pterygium of Both Eyes, Pterygium","enrollment":70},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT06510426","phase":"PHASE2","title":"Early Interferon-beta Treatment for West-Nile Virus Infection","status":"RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2024-07-14","conditions":"West Nile Virus, West Nile Fever Encephalitis, West Nile Fever Myelitis","enrollment":100},{"nctId":"NCT05936229","phase":"PHASE1, PHASE2","title":"Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-04-01","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT00771043","phase":"PHASE4","title":"A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2008-11-01","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT06019130","phase":"PHASE2","title":"Nivolumab in Children and Adults With Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"German Society for Pediatric Oncology and Hematology GPOH gGmbH","startDate":"2023-01-10","conditions":"Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharyngeal Neoplasms","enrollment":57},{"nctId":"NCT04472975","phase":"","title":"Prescription Drug Safety and Effectiveness in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"1996-01-01","conditions":"Multiple Sclerosis","enrollment":35000},{"nctId":"NCT04183491","phase":"PHASE1","title":"Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2020-02-28","conditions":"Healthy Subjects, Pharmacokinetics, Pharmacodynamics","enrollment":84},{"nctId":"NCT03399981","phase":"","title":"Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-06-01","conditions":"Progressive Multifocal Leukoencephalopathy","enrollment":80327},{"nctId":"NCT01412333","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09-20","conditions":"Relapsing Multiple Sclerosis","enrollment":835},{"nctId":"NCT01247324","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08-31","conditions":"Relapsing Multiple Sclerosis","enrollment":821},{"nctId":"NCT04324463","phase":"PHASE3","title":"Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2020-04-21","conditions":"Coronavirus, Severe Acute Respiratory Syndrome","enrollment":6667},{"nctId":"NCT05735067","phase":"","title":"The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"German University in Cairo","startDate":"2022-02-01","conditions":"Multiple Sclerosis","enrollment":138},{"nctId":"NCT04356339","phase":"","title":"US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-11-24","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT02486640","phase":"","title":"Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-08","conditions":"Multiple Sclerosis","enrollment":162},{"nctId":"NCT04860518","phase":"PHASE2","title":"Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19","status":"TERMINATED","sponsor":"Faron Pharmaceuticals Ltd","startDate":"2021-08-23","conditions":"Covid19","enrollment":7},{"nctId":"NCT02903537","phase":"PHASE1","title":"Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)","status":"UNKNOWN","sponsor":"Fundació Institut Germans Trias i Pujol","startDate":"2017-07-06","conditions":"Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive","enrollment":16},{"nctId":"NCT04079088","phase":"PHASE2","title":"Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2021-06-30","conditions":"Relapsing Multiple Sclerosis","enrollment":""},{"nctId":"NCT04655222","phase":"","title":"Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program","status":"COMPLETED","sponsor":"Biogen","startDate":"2021-04-30","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":470},{"nctId":"NCT02937285","phase":"PHASE3","title":"National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2010-12-06","conditions":"Multiple Sclerosis","enrollment":35},{"nctId":"NCT04732949","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19","status":"COMPLETED","sponsor":"Synairgen Research Ltd.","startDate":"2021-01-12","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19","enrollment":623},{"nctId":"NCT05298670","phase":"PHASE2","title":"Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"German University in Cairo","startDate":"2022-02-01","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT02727907","phase":"PHASE2, PHASE3","title":"Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2015-02-12","conditions":"Multiple Sclerosis","enrollment":163},{"nctId":"NCT03570359","phase":"PHASE2","title":"A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza","status":"COMPLETED","sponsor":"Synairgen Research Ltd.","startDate":"2018-01-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":122},{"nctId":"NCT00246324","phase":"PHASE4","title":"Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2003-12","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT04834401","phase":"","title":"Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis","status":"COMPLETED","sponsor":"St. Barnabas Medical Center","startDate":"2021-03-22","conditions":"Multiple Sclerosis, Covid19","enrollment":45},{"nctId":"NCT01037907","phase":"PHASE2","title":"A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"TERMINATED","sponsor":"Boston Scientific Corporation","startDate":"2009-11","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":173},{"nctId":"NCT01994018","phase":"","title":"Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake","status":"COMPLETED","sponsor":"OSF Healthcare System","startDate":"2011-11","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT02923466","phase":"PHASE1","title":"Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors","status":"COMPLETED","sponsor":"Vyriad, Inc.","startDate":"2017-04-17","conditions":"Malignant Solid Tumour","enrollment":76},{"nctId":"NCT00605215","phase":"PHASE3","title":"BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2008-04-24","conditions":"Multiple Sclerosis","enrollment":1331},{"nctId":"NCT02921035","phase":"","title":"Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2016-06-30","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":594},{"nctId":"NCT02584829","phase":"PHASE1, PHASE2","title":"Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2015-11-06","conditions":"Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7","enrollment":8},{"nctId":"NCT04492475","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 3 (ACTT-3)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":"COVID-19","enrollment":969},{"nctId":"NCT05024006","phase":"NA","title":"Public Health Emergency: SOLIDARITY TRIAL Philippines","status":"COMPLETED","sponsor":"University of the Philippines","startDate":"2020-04-23","conditions":"Covid19","enrollment":1314},{"nctId":"NCT00176592","phase":"PHASE4","title":"Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2003-01","conditions":"Multiple Sclerosis","enrollment":75},{"nctId":"NCT01975298","phase":"PHASE3","title":"A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-01","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT00000695","phase":"PHASE1","title":"Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":36},{"nctId":"NCT02744222","phase":"PHASE2, PHASE3","title":"Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-08-10","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":399},{"nctId":"NCT03808142","phase":"","title":"PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-02-20","conditions":"Multiple Sclerosis","enrollment":79},{"nctId":"NCT04032171","phase":"PHASE3","title":"Study of Evobrutinib in Participants With RMS","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-09-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":1},{"nctId":"NCT04032158","phase":"PHASE3","title":"Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-08-26","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":3},{"nctId":"NCT04647669","phase":"PHASE3","title":"World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments","status":"UNKNOWN","sponsor":"The University of The West Indies","startDate":"2021-06-01","conditions":"Covid19","enrollment":100},{"nctId":"NCT02047734","phase":"PHASE3","title":"Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-12-03","conditions":"Relapsing Multiple Sclerosis","enrollment":1320},{"nctId":"NCT03119701","phase":"PHASE2","title":"Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA","status":"TERMINATED","sponsor":"Faron Pharmaceuticals Ltd","startDate":"2017-02-18","conditions":"Preventive Medicine, Multi Organ Failure","enrollment":40},{"nctId":"NCT01623596","phase":"PHASE4","title":"Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06-08","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":881},{"nctId":"NCT00986960","phase":"PHASE2","title":"Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)","status":"WITHDRAWN","sponsor":"University at Buffalo","startDate":"2009-12","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT04647695","phase":"PHASE2","title":"IFN-beta 1b and Remdesivir for COVID19","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-11-20","conditions":"Covid19","enrollment":100},{"nctId":"NCT02294058","phase":"PHASE3","title":"Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-12-03","conditions":"Multiple Sclerosis","enrollment":1346},{"nctId":"NCT03177083","phase":"PHASE4","title":"Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy","status":"COMPLETED","sponsor":"Biogen","startDate":"2017-01-30","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":80},{"nctId":"NCT00031083","phase":"PHASE1","title":"Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas","status":"COMPLETED","sponsor":"Biogen","startDate":"2002-04-02","conditions":"Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed","enrollment":12},{"nctId":"NCT00436826","phase":"PHASE2","title":"A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2006-11-30","conditions":"Multiple Sclerosis","enrollment":172},{"nctId":"NCT00085670","phase":"","title":"Cytokine Gene Polymorphisms in Bone Marrow Failure","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-02-11","conditions":"Bone Marrow Diseases","enrollment":79},{"nctId":"NCT04521400","phase":"PHASE2","title":"the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-08-20","conditions":"Covid19","enrollment":100},{"nctId":"NCT00273364","phase":"PHASE2","title":"Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2005-11-16","conditions":"Multiple Sclerosis","enrollment":110},{"nctId":"NCT04494399","phase":"PHASE2","title":"IFN Beta-1b and Ribavirin for Covid-19","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-07-29","conditions":"Covid19","enrollment":96},{"nctId":"NCT04350281","phase":"PHASE2","title":"Double Therapy With IFN-beta 1b and Hydroxychloroquine","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2020-04-09","conditions":"COVID","enrollment":60},{"nctId":"NCT04465695","phase":"PHASE2","title":"Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-07-14","conditions":"COVID-19","enrollment":81},{"nctId":"NCT04460547","phase":"","title":"Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic","status":"UNKNOWN","sponsor":"Qassim University","startDate":"2020-07-25","conditions":"COVID-19","enrollment":200},{"nctId":"NCT02845843","phase":"PHASE2, PHASE3","title":"MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b","status":"COMPLETED","sponsor":"King Abdullah International Medical Research Center","startDate":"2016-07","conditions":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","enrollment":95},{"nctId":"NCT00066404","phase":"PHASE1","title":"Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2003-04","conditions":"Cancer","enrollment":""},{"nctId":"NCT04343768","phase":"PHASE2","title":"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-09","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04350671","phase":"PHASE4","title":"Interferon Beta 1a in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04350684","phase":"PHASE4","title":"Umifenovir in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-04-15","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04276688","phase":"PHASE2","title":"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2020-02-10","conditions":"Novel Coronavirus Infection","enrollment":127},{"nctId":"NCT02622724","phase":"PHASE3","title":"Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)","status":"TERMINATED","sponsor":"Faron Pharmaceuticals Ltd","startDate":"2015-12-23","conditions":"Respiratory Distress Syndrome, Adult","enrollment":301},{"nctId":"NCT00299962","phase":"PHASE1","title":"Gene Therapy for Pleural Malignancies","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2006-03","conditions":"Pleural Mesothelioma, Metastatic Pleural Effusions","enrollment":17},{"nctId":"NCT04289675","phase":"","title":"Multiple Sclerosis: Chi3L1 and Treatment Efficacy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2012-01-01","conditions":"Multiple Sclerosis","enrollment":63},{"nctId":"NCT03387046","phase":"PHASE2","title":"A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-03-26","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":7},{"nctId":"NCT03614715","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2017-11-27","conditions":"Bioequivalence, Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"BLOOD PRESSURE INCREASED"},{"count":2,"reaction":"INJECTION SITE ERYTHEMA"},{"count":2,"reaction":"MYOCARDIAL INFARCTION"},{"count":1,"reaction":"BODY TEMPERATURE INCREASED"},{"count":1,"reaction":"CARDIAC PROCEDURE COMPLICATION"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"CORONARY ARTERY THROMBOSIS"},{"count":1,"reaction":"COVID-19"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"DEPRESSED LEVEL OF CONSCIOUSNESS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Interferon Beta 1","genericName":"Interferon Beta 1","companyName":"University of Turin, Italy","companyId":"university-of-turin-italy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon Beta-1 activates interferon signaling pathways to enhance immune responses and reduce inflammatory cytokine production. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}